Incidence, severity and treatment outcome of tuberculosis in the era of the COVID-19 pandemic, France, 2018-2023 - 23/10/24

Doi : 10.1016/j.jeph.2024.202795

Jean-Paul Guthmann ^1,^⁎ , Jérôme Robert ^2,³, Delphine Viriot ¹, Isabelle Parent du Chatelet ¹
¹ Santé publique France, Direction des maladies infectieuses, Saint-Maurice, France
² Centre National de Référence de Mycobactéries et le la résistance des Mycobactéries aux antituberculeux, Bactériologie-Hygiène, DMU BioGemH, APHP.Sorbonne Université, Paris, France
³ Sorbonne Université, Inserm U.1135, Centre d'immunologie et des maladies infectieuses (Cimi), Paris, France

^⁎Correspondence: Jean-Paul Guthmann, 12 Rue du Val d'Osne, 94410, Saint-Maurice12 Rue du Val d'OsneSaint-Maurice94410

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Sous presse. Manuscrit accepté. Disponible en ligne depuis le Wednesday 23 October 2024
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Highlights

•	High quality and complete data are necessary to describe trends of tuberculosis epidemiology and assess how these trends may vary as a consequence of external events such as the COVID-19 pandemic;
•	Discussing reasons why specific social and medical interventions might have impacted the incidence of TB should help to organise and better manage health system disruptions in case of new crisis onset;
•	Tuberculosis is still an important public health problem in special groups of the EU population such as immigrants and homeless persons and should deserve significant efforts in order to meet the WHO targets of TB elimination;
•	Documenting treatment outcome deserves a major attention in countries where this information is largely missing, such as in France.

Le texte complet de cet article est disponible en PDF.

Abstract

Introduction

In France, the average steady decline in tuberculosis (TB) incidence close to 5% per year over the past half-century has been occasionally interrupted by disruptions related to external events. We describe the impact of the COVID-19 pandemic on TB incidence, severity and treatment outcome.

Methods

We analysed the number of TB cases and treatment outcomes reported through the mandatory notification system through 2018-2023. We compared cases reported, notification rates and percentage of cases completing treatment before and after the occurrence of the COVID-19 pandemic.

Results

The TB rate and the mean weekly number of cases decreased from 7.6/100,000 to 6.8/100,000 (-10%) (p=0.96) between 2019 and 2020. This decreasing trend continued, albeit more moderately, in 2021 (-7%) and 2022 (-2%). The trend shifted upward in 2023 (7.1/100,000, +15% compared to 2022). The mean weekly number of reported cases significantly decreased between 2018 (n=97), 2019 (n=97) and 2020 (n= 88) (p<0.01) and significantly increased between 2022 (n=77) and 2023 (n=91) (p<0.01). There was no increase in the number of severe cases, multidrugresistant (MDR) cases or deaths in the years following the pandemic. The proportion of persons that completed treatment was 83.3% for cases notified in 2022, a significant increase compared to the 79.7% estimated for 2019 cases (p<0.01). However, less than half of the reported cases had information on treatment outcome.

Conclusion

The important fall in TB incidence in France in 2020 is likely explained among other factors by the social and health measures that were implemented soon after the onset of the COVID-19 pandemic. In 2023, the situation had reversed although no impact on severe and MDR cases and deaths was observed.

Le texte complet de cet article est disponible en PDF.